Roflumilast + Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation
Conditions
Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation
Trial Timeline
Feb 1, 2012 → Mar 1, 2014
NCT ID
NCT01473758About Roflumilast + Placebo
Roflumilast + Placebo is a phase 2 stage product being developed by AstraZeneca for Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation. The current trial status is terminated. This product is registered under clinical trial identifier NCT01473758. Target conditions include Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01509677 | Phase 3 | Completed |
| NCT01473758 | Phase 2 | Terminated |
| NCT01443845 | Approved | Completed |
| NCT01329029 | Approved | Completed |
| NCT00424268 | Phase 3 | Completed |
| NCT00313209 | Phase 3 | Completed |
| NCT00297115 | Phase 3 | Completed |
| NCT00297102 | Phase 3 | Completed |
| NCT00242320 | Phase 3 | Completed |
| NCT01365533 | Phase 2 | Completed |
Competing Products
20 competing products in Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| macitentan 10 mg | BML, Inc. | Phase 3 | 76 |
| KPL-716 + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| TERN-701 | Terns Pharmaceuticals | Phase 1/2 | 38 |
| Fludarabine + Cyclophosphamide + PRGN-3007 | Precigen | Phase 1 | 28 |
| LY3556050 + Placebo | Eli Lilly | Phase 2 | 52 |
| THB001 | Third Harmonic Bio | Phase 1 | 25 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 33 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 33 |
| Briquilimab | Jasper Therapeutics | Phase 2 | 44 |
| Empagliflozin + Matching placebo | Eli Lilly | Phase 3 | 77 |
| LY3461767 + Placebo | Eli Lilly | Phase 1 | 33 |
| Pirtobrutinib + Venetoclax + Rituximab | Eli Lilly | Phase 3 | 77 |
| LY3526318 + Placebo | Eli Lilly | Phase 2 | 52 |
| Pirtobrutinib | Eli Lilly | Phase 2 | 52 |
| Ibrutinib + LY3214996 | Eli Lilly | Phase 1 | 33 |
| Pirtobrutinib + Acalabrutinib | Eli Lilly | Phase 2 | 52 |
| LYR-210 | Lyra Therapeutics | Phase 2 | 44 |
| LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2) | Lyra Therapeutics | Phase 2 | 44 |
| 480 Mometasone Furoate Sinus Drug Depot | Lyra Therapeutics | Phase 1 | 25 |
| LYR-210 + Sham procedure control | Lyra Therapeutics | Phase 3 | 69 |